selective anti tumor function of reic dkk 3

... iron in the active site of [NiFe]-hydrogenases NiFe 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 (CN) 2CO, Biology’s way to activate H2 J Biol Chem 274, 33 31– 33 37 Massanz, C & Friedrich, ... 40.7– 43. 0 13. 3–15.8 6.9–7.7 74.0–78.4 36 .4–52 .3 14.0–18.5 41.6–47.5 Ó FEBS 2004 804 E van der Linden et al (Eur J Biochem 271) Table Release of FMN upon reduction of the SH and effect on the NADH-K3Fe(CN)6 ... effect of FMN, but not of FAD or riboflavin, has been noticed earlier [36 ,37 ] Figure shows the effect of the FMN concentration on the reconstitution of the activity of the reduced SH Addition of about...

Ngày tải lên: 07/03/2014, 15:20

... 1.8 1 .3 Total NK cells (×109) NK cells (%) (24) (16) 1.2 8 .3 (69) 1.9 ( 23) 1.4 4 .3 (31 ) 0.9 (20) 1.7 5.8 (34 ) 1.4 (24) 1.7 6 .3 (37 ) 1.4 ( 23) 1 .3 5.1 (39 ) 1.2 ( 23) 1.2 6.9 (58) 1.7 (25) Page of 18 ... Journal of Translational Medicine 2009, 7:50 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, density, and location of immune ... 6 .3 (7) 10.2 34 7 3. 4 (9) 10 .3 126 3. 3 ( 13) 11.1 115 3. 0 ( 13) 11.7 145 percentage of CD3+ T cells remained unaffected by the stimulation with TKD/IL-2 however, between leukapheresis L3 and L6 the...

Ngày tải lên: 18/06/2014, 15:20

... Autoimmunity 2005, 38 :35 9 -36 7 Page of 30 Furchgott R, Cherry P, Zawadzki J, Jothianandan D: Endothelial cells as mediators of vasodilation of arteries J Cardiovasc Pharmacol 1984, 6: S 336 -34 3 31 Wei X, ... milk solution for h They were then incubated with anti- TNF-a, anti- IL1b, anti- IL-6, anti- iNOS, anti- COX-2, anti- p-IBa, or anti- p65 monoclonal antibodies for h and subsequently washed times with ... Seoul 139 -742, Republic of Korea 2School of Life Sciences, Handong Global University, Pohang 791-708, Republic of Korea 3College of Pharmacy, Chungbuk National University, Cheongju 36 1-7 63, Republic...

Ngày tải lên: 11/08/2014, 03:20

... Autoimmunity 2005, 38 :35 9 -36 7 Page of 30 Furchgott R, Cherry P, Zawadzki J, Jothianandan D: Endothelial cells as mediators of vasodilation of arteries J Cardiovasc Pharmacol 1984, 6: S 336 -34 3 31 Wei X, ... milk solution for h They were then incubated with anti- TNF-a, anti- IL1b, anti- IL-6, anti- iNOS, anti- COX-2, anti- p-IBa, or anti- p65 monoclonal antibodies for h and subsequently washed times with ... Seoul 139 -742, Republic of Korea 2School of Life Sciences, Handong Global University, Pohang 791-708, Republic of Korea 3College of Pharmacy, Chungbuk National University, Cheongju 36 1-7 63, Republic...

Ngày tải lên: 11/08/2014, 06:23

... 5000 4000 Tumor volume mm 6000 Tumor volume http://www.gvt-journal.com/content/7/1/10 30 00 2000 1000 5000 4000 30 00 2000 1000 0 10 15 20 25 30 35 10 40 Days after CT26 challenge 20 25 30 35 40 Days ... 20% 0% 0% 10 20 30 40 50 60 Days after CT26 challenge 10 20 30 40 50 60 Days after 4T1 challenge Figure Induction of therapeutic anti- tumor immunity Induction of therapeutic anti- tumor immunity ... 60% 40% 20% 20 30 40 50 Days after CT26 challenge 60 0% 10 20 30 40 50 60 Days af ter 4T1 challenge Figure Induction of protective anti- tumor immunity Induction of protective anti- tumor immunity...

Ngày tải lên: 14/08/2014, 19:22

... 42 2 .3. 3.2 Extraction of LGG cytoplasmic fraction………………………… 42 2 .3. 3 .3 Optimization of cytotoxic molecule production ………………… 42 2 .3. 3.4 Growth curve of LGG in media…………………………………… 43 2 .3. 3.5 Measurement ... Co-culture of immune cells with Lactobacilli …………………………… 33 2.2 .3. 1 Co-culture of neutrophils or DCs with LGG …………………… 33 2.2 .3. 2 Study of neutrophil-neutrophil interaction……………………… 34 2.2 .3. 3 DC neutrophil ... Macrophages…………………………………………… 22 1.6 .3. 3.2 Dendritic cells………………………………………… 22 1.6 .3. 3 .3 Neutrophils…………………………………………… 23 1.6 .3. 3.4 Dendritic cell and neutrophil interaction……………… 23 1.7 Scope of study…………………………………………………………………...

Ngày tải lên: 11/09/2015, 09:16

... ROS 29 ACTIVATION OF PRO SURVIVAL SIGNALS IN ONCOGENECITY 31 3. 1 Oncogenes and oncoproteins 31 ii 3. 1.1 PI3K 32 3. 1.2 PI3K-Akt signaling in cancer 33 3. 1 .3 Akt at the crossroads of oncogenic and ... suppressor networks 36 ROS OF ROS IN DEVELOPMENT OF ONCOGENECITY 37 4.1 Types of ROS 38 4.2 Intracellular sources of ROS 38 4 .3 Evidence of the prooxidant state in oncogenesis 40 4 .3. 1 Role of O2- in oncogenesis ... oligomerization of DR5 127 Figure 33 LY30 enhances DISC assembly 129 Figure 34 LY30 enhances caspase activation and loss of pro Bid 130 Figure 35 LY30-TRAIL treated cells show mTOR activation 132 Figure 36 ...

Ngày tải lên: 14/09/2015, 18:22

... Apoptosis 31 1 .3. 3 Apoptosis pathways 34 1 .3. 3.1 Receptor-mediated apoptosis 34 1 .3. 3.2 Mitochondrial-mediated apoptosis 35 1 .3. 4 Apoptosis and cancer 36 1 .3. 5 TNFR signaling pathway 37 1 .3. 5.1 TNF-induced ... Anti- hypertension 1.1 .3. 3 Anti- eye irritation 1.1 .3. 4 Anti- ulcerative colitis 1.1 .3. 5 Anti- inflammatory activity 10 1.1 .3. 6 Anti- tumor activities 10 1.2 PHARMACOLOGICAL MECHANISMS OF LUTEOLIN 1.2.1 ... TNF-induced apoptosis 38 1 .3. 5.2 TNF-induced NF-κB activation 38 1 .3. 5 .3 TNF-induced JNK activation 39 1 .3. 5.4 Regulation of TNF-induced apoptosis 40 1 .3. 6 TRAIL signaling pathway 40 1 .3. 6.1 TRAIL-induced...

Ngày tải lên: 15/09/2015, 17:11

... 165, 32 68 32 74 30 Class R, Lindman S, Fassbender C, Leinenbach HP, Rawer S, Emrich JG, Brady LW & Zeppezauer M (1996) 437 2 31 32 33 34 35 36 37 38 39 40 41 42 Histone H1 suppresses tumor growth of ... FEBS Journal 2 73 (2006) 436 0– 437 3 ª 2006 The Authors Journal compilation ª 2006 FEBS 436 3 Histone H4 mRNA variants R Poirier et al Fig Comparison between the structures of the ORF of H4 somatic ... Biochim Biophys Acta 139 6, 32 38 Poirier R, Lemaire I, Dumont M, Leduc N, Le HT & Lemaire S (2005) Correlation between the expression of FEBS Journal 2 73 (2006) 436 0– 437 3 ª 2006 The Authors Journal...

Ngày tải lên: 16/03/2014, 13:20

... (20 03) a-Lactalbumin unfolding is not sufficient to cause apoptosis, but is required for 4624 35 36 37 38 39 40 41 42 43 44 45 46 the conversion to HAMLET (human a-lactalbumin made lethal to tumor ... J Mol Biol 39 8, 35 1 36 1 Duringer C, Hamiche A, Gustafsson L, Kimura H & Svanborg C (20 03) HAMLET interacts with histones and chromatin in tumor cell nuclei J Biol Chem 278, 42 131 –42 135 Fischer ... H NMR spectrum of ELOA, showing up-field shifts of the resonance of bound oleic acid compared with those of free molecules The 1H NOESY spectrum of ELOA demonstrated the presence of cross-peaks...

Ngày tải lên: 29/03/2014, 21:20

... R H p-eNOS eNOS B H1 R1 H2 R2 H3 R3 H1 R1 H2 R2 H3 R3 H1 R1 H2 R2 H3 R3 p-Akt Akt p-ERK1/2 ERK1/2 p-eNOS eNOS C Phosphorylation (fold-induction R3 vs H3) ** PI3K ⁄ Akt and eNOS inhibitors exert ... angiogenesis [32 ,33 ] In conclusion, this study offers new insights into the impact of cyclic hypoxia on vascular cells, an underestimated component of the tumor stroma in terms of phenotypic ... caveolin are key tar- 34 35 36 37 38 gets for the proangiogenic nitric oxide-mediated effects of statins Circ Res 89, 866–8 73 Powis G, Ihle N & Kirkpatrick DL (2006) Practicalities of drugging the...

Ngày tải lên: 30/03/2014, 02:20

... 9.76 6.68 0.60 3. 90 9.76 6.68 0.60 3. 90 8.47 7 .32 – – 8.47 7 .32 _ – 4.58 4.20 3. 01 5.11 7.70 7.62 – – 7.70 7.62 – – 3. 27 5.68 9.49 6 .35 8. 63 3.00 7. 13 6.56 7.67 4.46 3. 93 6.10 7.81 7 .34 7.18 4.88 ... Phe3 a Phe3 a Phe3 b2 Phe4 Phe4 Phe4 Phe4 Phe4 Phe4 Phe4 2,6H 3, 5H 2,6H 3, 5H b2 2,6H NH Weak Weak Weak Weak Weak Medium Weak Tyr1 2,6H Phe3 2,6H Phe3 2,6H Phe3 2,6H Phe3 3, 5H Phe3 3, 5H Phe3 Phe4 ... 2,-z x,y +1,z x,y,z x,y-1,z x,y,z x,y-1,z 3. 024(4) 2.7 83( 5) 3. 016(4) 3. 138 (5) 3. 021(5) 2.776(5) 3. 2 73( 5) 3. 122(5) 2.814(4) 2.848(5) 3. 221(4) 2.767(5) 3. 0 83( 5) x,y,z x,y,z 1-x,y-1 ⁄ 2,-z 1-x,y-1...

Ngày tải lên: 30/03/2014, 20:20

... http://www.translational-medicine.com/content/9/1/7 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours Eur J Cancer 20 03, 39 :917-926 Dechantsreiter MA, ... the rate of metastasis to the kidney Br J Cancer 20 03, 88 :32 7 -33 3 38 Crawford TN, Alfaro DV, Kerrison JB, Jablon EP: Diabetic retinopathy and angiogenesis Curr Diabetes Rev 2009, 5:8- 13 39 Santulli ... to solid tumors [17 ,37 ], diabetic retinopathy [38 ,39 ] and inflammatory disease [36 ] Conclusions The present study indicates the importance of RGDechiHCit in the selective inhibition of endothelial...

Ngày tải lên: 18/06/2014, 16:20

... absorption peak of PHPP from 39 9 to 409 nm (c) Spectrum (d) indicated absorptions of SMNPs and HCl at 240, 31 4, and 36 4 nm, demonstrating that the 240, 31 4, and 36 4 nm peak of the spectrum (e) attributed ... 125, 7860 (20 03) doi:10.1021/ja 034 3095 S Wang, R Gao, F Zhou, M Selke, J Mater Chem 14, 487 (2004) doi:10.1 039 /b311429e R De Gao, H Xu, M Philbert, R Kopelman, Nano Lett 6, 238 3 (2006) doi:10.1021/nl0617179 ... calf serum) using a dilution factor of to varied concentrations: 0, 0. 03, 0. 13, 0.64, 3. 20, 16.00, and 80 lmol L-1 Biosafety Assessment SW480 carcinoma cells (3 1 03 cells per well) were seeded in...

Ngày tải lên: 22/06/2014, 01:20

... of anti- CD3 mAb plus JTA009 (ICOS co-stimulation), anti- CD3 mAb plus anti- CD28 mAb (CD28 co-stimulation), anti- CD3 mAb plus JMAb 23 (anti- CD3), or without stimulation for days IgG anti- dsDNA antibody ... Buckwalter S, Ledbetter JA, Clark EA: Characteriza- 22 23 24 25 26 27 28 29 30 31 32 33 34 35 tion of human inducible costimulator ligand expression and function J Immunol 2000, 164:4689-4696 Ling V, ... http://arthritis-research.com/content/8 /3/ R62 Table Characterization of JTA009 JTA009 (%) SA12 (%) P CD4+ICOS+/CD4+ 29.2 ± 22.1 3. 8 ± 2.4 0.0 033 CD8+ICOS+/CD8+ 11.6 ± 11.2 1.6 ± 1.0 0.0 033 CD4+CD45RO+ICOS+/CD4+CD45RO+ 37 .3 ± 25.8...

Ngày tải lên: 09/08/2014, 07:20

... Hochberg MC, VIGOR Page of (page number not for citation purposes) 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen ... Indomethacin 58 1 .39 Etodolac 39 0.55 Rofecoxib 37 0.80 Diflusinal 33 1.68 Ketoprofen 28 1.42 Meloxicam 26 0.85 Etoricoxib 21 0.90 Diclofenac 21 0.50 Azapropazone 20 1.00 Suoprofen 20 1.80 Nefopam ... Initial blood loss at start of trial 38 950 0.46 Placebo arm of treatment 14 172 0.76 Aspirin (>1,800 mg/day) 29 36 1 5.01 Aspirin (32 5 mg/day) 64 1.61 Ibuprofen 66 2. 03 Fenoprofen 62 1.86 Piroxicam...

Ngày tải lên: 09/08/2014, 10:22

... multifactorial nature of the response prediction The results of this and other biomarker studies look promising, but full confirmation of the biomarker profiles in independent uniform cohorts is of the utmost ... American College of Rheumatology (ACR) criteria for improvement (greater than or equal to ACR 50% improvement criteria response) An integrated analysis of a relevant set of 14 autoantibody specificities ... in a combined set of 93 samples consisting of three independent cohorts (a USbased Autoimmune Biomarkers Collaborative Network [ABCoN] cohort [n = 29], a Swedish cohort [n = 43] , and a Japanese...

Ngày tải lên: 09/08/2014, 14:21

... Naïve B cells ** 400 200 30 0 30 0 200 100 0 pre anti- TNF pre anti- TNF post anti- TNF C post anti- TNF ** * 200 100 Memory 100 pre anti- TNF post anti- TNF 1200 Anti- MCV (U/ml) 30 0 Naïve 200 D *** 400 ... diseases, such as SLE [30 -33 ], systemic sclerosis [34 ], asthma [35 ], and irritable bowel syndrome [36 ] Presumably, constant stimulation of autoantigens through BCR and the influence of other proinflammatory ... titers of anti- MCV antibodies (P = 0. 033 ) (Figure 5b) We obtained similar results when we measured anti- ccp antibodies (data not shown) To evaluate whether this association was restricted to autoantibodies,...

Ngày tải lên: 12/08/2014, 12:20

... History of prior anti- TNF therapy Prior ETN or IFX or both 115 /30 5 (37 .7) No prior ETN/IFXa 518/8 73 (59 .3) 0.41 (0 .32 to 0.54) < 0.001 128 /31 4 (40.8) 0.40 (0 .31 to 0. 53) < 0.001 27/81 (33 .3) 0.98 ... with ETN, the BASDAI 50 response rates at week 12 were 33 .3% for loss of response (n = 33 ), 33 .3% for intolerance (n = 12), and 32 % for lack of response (n = 12) The pattern for ASAS40 response ... 0. 033 75/156 (48.1) 1.82 (1. 03 to 3. 20) 561/890 ( 63. 0) Prior TNF antagonist(s) ETN only 25/81 (30 .9) 0. 93 (0.47 to 1. 83) IFX only 66/150 (44.0) 1.64 (0.91 to 2. 93) ETN and IFXa 0.0 83 24/74 (32 .4)...

Ngày tải lên: 12/08/2014, 14:22

... Baylac, 31 300 Toulouse, France, 2Centre of Rheumatology, CHU Purpan, 1, place Baylac, BP 30 28, 31 024 Toulouse, France and 3INSERM U558, Toulouse, Faculté de Médecine, 37 , allées Jules Guesde, 31 0 73 ... link between anti- TNF treatment and reactivation of CMV Our present data argue in favor of the maintenance of anti- CMV immunity during anti- TNF treatments This is of importance in light of previous ... [3] , longterm safety of TNF blockers requires longer follow-up regarding HCV [3, 39] Regarding EBV, a member of the herpes family, the risk of lymphoma has been debated [3] The anti- EBV response...

Ngày tải lên: 12/08/2014, 14:22